99% + Purity Almitrine Dimesylate CAS 29608-49-9
Product Summary:
Almitrine bismesylate is a pharmacologically unique respiratory stimulant. It enhances respiration after both acute and chronic administration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. In comparison with traditional central-acting respiratory stimulants, almitrine has advantages of oral activity, prolonged duration of effect, and an improved adverse effect profile. |
99% + Purity Almitrine Dimesylate CAS 29608-49-9
Name:Almitrine Dimesylate
CAS No.:29608-49-9
Synonyms:ALMITRINE BISMESYLATE;ALMITRINE DIMESYLATE;2,4-bis(allylamino)-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine dimethanesulfonate;n,n'-diallyl-6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1,3,5-triazine-2,4-diamine dimethanesulphonate;ALMITRINE DIMESILATE;N,N'-Diallyl-6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1,3,5-triazine-2,4-diamine dimethanesulphonate;Mesylate AlMitrine;N2,N4-Diallyl-6-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1,3,5-triazine-2,4-diamine dimethanesulfonate
Purity: 99.0%Min
Molecular Formula:C28H37F2N7O6S2
Molecular Weight:669.76
Appearance:White crystalline powder
Almitrine Dismesylate Description:
Almitrine Dismesylate is a pharmacologically unique respiratory stimulant. It enhances respiration after both acute and chronic administration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. In comparison with traditional central-acting respiratory stimulants, almitrine has advantages of oral activity, prolonged duration of effect, and an improved adverse effect profile. Almitrine is generally well tolerated, with headache and minor gastrointestinal disturbances being the most frequently observed side effects. This investigational agent has been shown to increase arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease both at rest and during exercise through increased ventilation and improved ventilation/perfusion matching. It may also prove useful in the treatment of nocturnal oxygen desaturation because of its ability to reduce the frequency and severity of nocturnal hypoxemia without impairing the quality of sleep. Additional research is needed to further define the role of almitrine in the relief of hypoxemia.
Almitrine Dismesylate Uses:
Almitrine dismesylate has been used as a respiratory stimulant in acute respiratory failure associated with conditions such as chronic obstructive pulmonary disease.Usual oral dose from 50 to 100 mg daily and treatment many be intermittent.Up to 3 mg/kg has been given daily by intravenous infusion in 2 or 3 divided doses,each dose being infused over 2 hours.It is also available in a compound preparation with raubasine for mental function impairment in the elderly.